| Overview |
| bs-3809R-Cy5.5 |
| TP/thymidine phosphorylase Antibody, Cy5.5 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Specifications |
| Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Thymidine Phosphorylase |
| 121-220/482 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 1890 |
| Cytoplasm |
| ECGF 1; PDEGF; ECGF1; Endothelial cell growth factor 1; Endothelial cell growth factor 1 platelet derived; Gliostatin; hPD ECGF; MNGIE; PD ECGF; PDECGF; PDEGF; Platelet derived endothelial growth factor; TdRPase; TP; TYMP; Thymidine Phosphorylase; TYPH_HUMAN; TdRPase. |
| In the presence of inorganic orthophosphate, the platelet-derived endothelial growth factor (PD-ECGF) thymidine phosphorylase (TP) (gliostatin) catalyses the reversible phospholytic cleavage of thymidine and deoxyuridine to their corresponding bases and 2-deoxyribose-1-phosphate. It is both chemotactic and mitogenic for endothelial cells and a non-heparin binding angiogenic factor present in platelets. It is also involved in transformation of fluoropyrimidines, cytotoxic agents used in the treatment of a variety of malignancies, into active cytotoxic metabolites. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz